Overview: BCR ABL1 Tyrosine Kinase Mutation TestIntroduction: The BCR ABL1 Tyrosine Kinase Mutation Test detects BCR-ABL1 mutations to diagnose leukemia, causing fatigue or bruising. Following 2023 ASH guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected chronic myeloid leukemia.
Other Names: BCR-ABL1 Mutation Assay, CML Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: BCR-ABL1 testing began in the 1980s with leukemia research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects BCR-ABL1 mutations to diagnose leukemia, guides treatment, and evaluates patients with fatigue or bruising.
Test Parameters: 1. BCR-ABL1 Mutations
Pretest Condition: No fasting required. Collect whole blood or bone marrow. Report history of fatigue, bruising, or leukemia symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bruising, or history of leukemia. Include current medications, especially tyrosine kinase inhibitors.
Consent: Written consent required, detailing the tests purpose, leukemia implications, and risks of sample collection.
Procedural Considerations: Uses real-time PCR to detect BCR-ABL1 mutations (e.g., T315I). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for leukemia diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive BCR-ABL1 mutations confirm leukemia, guiding tyrosine kinase inhibitor therapy. Negative results may require cytogenetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Cytogenetic analysis, FISH, or bone marrow biopsy to confirm leukemia diagnosis.
Test Limitations: Specific to BCR-ABL1 mutations; other leukemia types may be missed. Sample quality affects sensitivity.
References: ASH Leukemia Guidelines, 2023; Journal of Clinical Oncology, Druker BJ, 2022.
